Home › Research › Risk factors
Few Alzheimer’s Patients Get State-of-Art Care
Jim Rosack. Psychiatric News, 2001-04-20
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Back to table of contents Previous article Next article Clinical & Research NewsFull AccessFew Alzheimer’s Patients Get State-of-Art CareJim RosackJim RosackSearch for more papers by this authorPublished Online:20 Apr 2001https://doi.org/10.1176/pn.36.8.0042Preliminary data suggest that a huge treatment gap exists in patients with Alzheimer’s disease, with as many as 65 percent of patients with the progressive and terminal disorder going undiagnosed and, therefore, untreated.This startling finding was just one of many discussed and debated at the annual meeting of the American Association for Geriatric Psychiatry (AAGP) in San Francisco in February.Several researchers and clinicians from various disciplines noted, once again, that the majority of patients with AD are not being seen by specialists, but rather by primary care physicians who do not always recognize and treat the disease.The significance of the problem was summed up by P. Many physicians, he explained, see the progressive course of the disease as unrelenting and see no value to treatment.Geriatric psychiatry specialists “haven’t yet convinced primary care physicians of the value of treatment for dementia and cognitive disorders associated with AD,” Doraiswamy said. “They thus have no real impetus to diagnose the disorder. The result is a large number of last-minute diagnoses that even a grocery store clerk could have made.”According to Doraiswamy, research indicates that as many as two-thirds of all cases of dementia in the community are not recognized or evaluated. What they do not understand is that the value of the medication lies in the fact that without that six to 12 months of cholinesterase inhibitor therapy, the cognitive function of the patient would be significantly worse.”Cholinesterase inhibitors (ChEIs) have only been available since the mid 1990s. The result of that action is a relative increase in available acetylcholine within the synapses of the brain neurons affected by AD. More recently, rivastigmine tartrate (Exelon) gained approval in April 2000, and galantamine hydrobromide (Reminyl) was approved February 28 (Original article: see story on page 43).Several of the AAGP annual meeting presentations focused on the use of these medications as well as new and developing medications that could expand treatment options for AD.Significant evidence now suggests, Doraiswamy said, that ChEIs may ease the loss of independence that patients feel, improve the patients’ ability to condu
What this study adds
Evidence grade: Low
The record lists 125 participants. Preliminary data suggested that many Alzheimer's patients go undiagnosed and untreated, partly because primary care physicians may not see value in treatment. This concerns diagnosis and care gaps, not a treatment, cure, or prevention for the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rosack, J. (2001). Few Alzheimer’s Patients Get State-of-Art Care. Psychiatric News. https://doi.org/10.1176/pn.36.8.0042
Vancouver
Rosack J. Few Alzheimer’s Patients Get State-of-Art Care. Psychiatric News. 2001. doi:10.1176/pn.36.8.0042.
BibTeX
@article{rosack2001-d4990f60,
author = {Rosack, Jim},
title = {{Few Alzheimer’s Patients Get State-of-Art Care}},
journal = {Psychiatric News},
year = {2001},
doi = {10.1176/pn.36.8.0042},
url = {https://doi.org/10.1176/pn.36.8.0042}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Back to table of contents Previous article Next article Clinical & Research NewsFull AccessFew Alzheimer’s Patients Get State-of-Art CareJim RosackJim RosackSearch for more papers by this authorPublished Online:20 Apr 2001https://doi.org/10.1176/pn.36.8.0042Preliminary data suggest that a huge treatment gap exists in patients with Alzheimer’s disease, with as many as 65 percent of patients with the progressive and terminal disorder going undiagnosed and, therefore, untreated.This startling finding was just one of many discussed and debated at the annual meeting of the American Association for Geriatric Psychiatry (AAGP) in San Francisco in February.Several researchers and clinicians from various disciplines noted, once again, that the majority of patients with AD are not being seen by specialists, but rather by primary care physicians who do not always recognize and treat the disease.The significance of the problem was summed up by P.
- Many physicians, he explained, see the progressive course of the disease as unrelenting and see no value to treatment.Geriatric psychiatry specialists “haven’t yet convinced primary care physicians of the value of treatment for dementia and cognitive disorders associated with AD,” Doraiswamy said. “They thus have no real impetus to diagnose the disorder.
- The result is a large number of last-minute diagnoses that even a grocery store clerk could have made.”According to Doraiswamy, research indicates that as many as two-thirds of all cases of dementia in the community are not recognized or evaluated.
- What they do not understand is that the value of the medication lies in the fact that without that six to 12 months of cholinesterase inhibitor therapy, the cognitive function of the patient would be significantly worse.”Cholinesterase inhibitors (ChEIs) have only been available since the mid 1990s.
- The result of that action is a relative increase in available acetylcholine within the synapses of the brain neurons affected by AD.
Why it matters
Preliminary data suggested that many Alzheimer's patients go undiagnosed and untreated, partly because primary care physicians may not see value in treatment. This concerns diagnosis and care gaps, not a treatment, cure, or prevention for the disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants125
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 26 of the 97 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Psychiatric News) |
| Journal's citation record | 0 / 4 | Psychiatric News: journal h-index 17 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 2 / 4 | 125 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 27 year(s) since 2001 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Jim Rosack: h-index 6 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 26 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 97 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk factors from nearby years
Also in Risk factors
383 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.